A new study in the journal JAMA helps break out exactly what is, and isn’t, killing Americans.
Heart disease is far and away the number one killer in this country (some 1 in 4 deaths are associated with it). But cancer, lung diseases, and metabolic disorders such as diabetes aren’t far behind.
Here is the good news-bad news situation, according to the report: “While cardiovascular disease (CVD) death rates declined by approximately 36% from 2000 to 2014, CVD remains the leading cause of mortality among US adults. Annual declines in CVD mortality slowed between 2011 and 2014 (0.7% fewer CVD deaths per year), and it appears unlikely that strategic goals from the American Heart Association (20% reduction by 2020) will be achieved.”
Put into simpler terms, diabetes and high blood pressure are still killing millions of people. And communities of color continue to be disproportionately affected by this reality.
Peloton goes from confidential IPO to actual IPO. The digitally-connected exercise firm Peloton (the one with the fancy, in-home bikes and treadmills that connect you online with coaches) is going public (again… sort of). Peloton had already filed for a confidential IPO earlier this year. But now it’s going the whole hog and filing for a Nasdaq public offering. The year of the digital health IPO continues! (Fortune)
Investors seem pretty OK with the J&J opioid ruling. Shareholders don’t appear to be sweating the $500 million-plus judgment levied against Johnson & Johnson for its alleged role in fueling the opioid epidemic. J&J shares are up nearly 2% since the landmark ruling announced Monday, which has been seen as a milestone in dozens of cases levied against drug makers and distributors for aggressively selling pain products. Why? The decision (contested by J&J) could have involved significantly more money. (Fortune)